Die Wirkung eines ß-Receptorenblockers auf das Herzminutenvolumen — Untersuchungen bei essentieller Hypertonie und hyperkinetischem Herzsyndrom unter Berücksichtigung der Plasma-Adrenalin- und Noradrenalinspiegel

Walter, Ingeborg; Kusus, T; Wagner, K.; Lydtin, H

doi:10.1007/978-3-642-47087-5_310

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In normotensive car drivers an oral dose of 40 mg oxprenolol given one hour before racing-car driving suppressed the tachycardia but did not change the increase in plasma catecholamine concentration. In contrast to this finding Walter et al (1973) found in patients with EH a significant decrease in plasma adrenaline concentration at rest after an intravenous injection of 1 mg prindolol. No difference was observed in resting pre-exercise catecholamine concentrations before and after beta blockade.…”

Section: Mean Arterial Bp I Mmhg)contrasting

confidence: 71%

Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension

1976

View full text Add to dashboard Cite

15 patients (4 females, 11 males, 21 to 55-year old) with mild to moderate essential hypertension (EH) were treated with placebo for two weeks and thereafter with increasing doses of prindolol (15 to 38 mg/day in the mean) and kept on a mean maintenance dosage of 32 mg/day for an average of 16 weeks in all. Blood pressure (BP), heart rate und plasma noradrenaline (PNA) concentrations were measured under standardized conditions (supine, standing, walking) at the end of two weeks on placebo and after the experimental treatment period. The results were compared to those of a group of 15 normotensive untreated control subjects (NS): after an average of 16 weeks on prindolol BP fell from 163/113 mm Hg to 129/91 mm Hg in the mean. PNA levels in EH before prindolol were significantly higher than in NS (supine: 272 +/- 22.0 ng/l (mean +/- SEM) vs. 135 +/- 15.1 ng/l, standing: 448 +/- 31.9 ng/l vs. 359 +/- 18.4 ng/l, walking: 388 +/- 22.5 ng/l vs. 234 +/- 22.1 ng/l). In EH chronic administration of prindolol led to a significant decrease in PNA concentrations under all the three test conditions to levels which did not differ significantly any more from those derived from NS. The adrenergic response to upright posture reflected in the percentage increase in PNA was significantly less in EH before prindolol when compared to the percentage increase in NS. On prindolol the adrenergic response was not abolidhed, yet it tended to approach the values found in NS. Before prindolol under resting conditions diastolic BP correlated closely with the corresponding PNA levels (p less than 0.01, r = 0.66, n = 15). This correlation could not be reestablished after prindolol treatment. The decrease in PNA after long-term treatment with prindolol was not correlated to the fall in blood pressure. The decrease in PNA indicates a lower activity of the sympathetic nervous system which may contribute to the antihypertensive effect of prindolol.

show abstract

Section: Mean Arterial Bp I Mmhg)contrasting

confidence: 71%

Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension

1976

View full text Add to dashboard Cite

show abstract

“…Accordingly the rise in plasma noradrenaline in no way excludes an effect of prejunctional Padrenoceptor blockade. Furthermore, it has been shown that during treatment with pindolol plasma noradrenaline does decrease (Walter et al, 1973;Anavekar et al, 1975;Brecht et al, 1976aBrecht et al, , 1976bLang et al, 1978;Winer et al, 1978;Franz et al, 1980, Gavras et al, 1981Kirsten et al, 1982;Wilcox et al, 1981), (Table 2). It has also been shown that in the course of treatment with practolol, the urinary excretion of catecholamines is reduced by 65 % (Esler & Nestel, 1973).…”

Section: Prejunctional8-adrenoceptor Theorymentioning

confidence: 99%

How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta‐adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Veld¹,

Schalekamp²

1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Several authors have found an increase in catecholamines during 13-adrenoceptor blocker therapy (Irving et al, 1974;Hansson & Hokfelt, 1975;Hansen et al, 1978) while others have found decreases (Walter et al, 1973;Brecht et al, 1976). Rahn et al (1978) mentioned that the increase in noradrenaline and adrenaline levels which they found after propranolol therapy is not compatible with the idea of the drug inhibiting transmitter release from sympathetic nerve endings.…”

Section: Discussionmentioning

confidence: 98%

Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta‐adrenoceptor blockade with and without intrinsic sympathomimetic activity.

Kirsten¹,

Heintz²,

Böhmer³

et al. 1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 This study was designed to follow changes in plasma catecholamine concentrations during ,B-adrenoceptor blockade using doses of antagonists which decreased the mean arterial pressure (MAP) by about 15 mm Hg. Noradrenaline, adrenaline and dopamine were radioenzymatically determined in 34 patients with moderate essential hypertension during an 8 week course of treatment with either pindolol (with intrinsic sympathomimetic activity, ISA) or propranolol (without ISA). Plasma catecholamines were determined before and 1, 7, 28 and 56 days after commencement of treatment and 1 week after discontinuation of treatment. 2 After one day of pindolol therapy plasma catecholamine concentrations were decreased, but no decrease in MAP was observed. After one day of propranolol therapy, however, MAP was decreased, but except for increased levels of adrenaline, plasma catecholamines showed no changes. 3 On the 56th day of therapy both 0-adrenoceptor blockers had decreased the MAP. Pindolol therapy had caused a decrease in all three catecholamines whereas propranolol had caused no change except for decreased dopamine levels. 4 One week after cessation of propranolol therapy catecholamines were decreased but the MAP had begun to return to initial values; after cessation of pindolol therapy however, the MAP remained decreased. 5 The dissimilar relationships between blood pressure and catecholamine concentration during pindolol and propranolol therapy are evidence for multiple and different modes of action for P-adrenoceptor blockers with and without ISA. This study demonstrates that catecholamine concentrations were generally decreased during low-dose P-adrenoceptor blocker therapy, with lower catecholamine levels during pindolol treatment than during propranolol treatment.

show abstract

Die Wirkung eines ß-Receptorenblockers auf das Herzminutenvolumen — Untersuchungen bei essentieller Hypertonie und hyperkinetischem Herzsyndrom unter Berücksichtigung der Plasma-Adrenalin- und Noradrenalinspiegel

Cited by 3 publications

References 8 publications

Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension

Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension

How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta‐adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta‐adrenoceptor blockade with and without intrinsic sympathomimetic activity.

Contact Info

Product

Resources

About